These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
62. Science and religion for COVID-19 vaccine promotion. Galang JRF J Public Health (Oxf); 2021 Sep; 43(3):e513-e514. PubMed ID: 33866364 [TBL] [Abstract][Full Text] [Related]
63. Implementation of State Vaccine Incentive Lottery Programs and Uptake of COVID-19 Vaccinations in the United States. Acharya B; Dhakal C JAMA Netw Open; 2021 Dec; 4(12):e2138238. PubMed ID: 34882179 [TBL] [Abstract][Full Text] [Related]
64. The Risk of Resurgence in Vaccine-Preventable Infections Due to Coronavirus Disease 2019-Related Gaps in Immunization. Feldman AG; O'Leary ST; Danziger-Isakov L Clin Infect Dis; 2021 Nov; 73(10):1920-1923. PubMed ID: 33580243 [TBL] [Abstract][Full Text] [Related]
65. Hypersensitivity Reactions to Vaccines: Current Evidence and Standards for SARS-CoV-2 Vaccines. Carvalho JC; Cunha F; Coutinho IA; Loureiro C; Faria E; Bom AT Acta Med Port; 2021 Jun; 34(7-8):541-547. PubMed ID: 34851819 [TBL] [Abstract][Full Text] [Related]
66. The world's largest COVID-19 vaccination campaign. Bagcchi S Lancet Infect Dis; 2021 Mar; 21(3):323. PubMed ID: 33639124 [No Abstract] [Full Text] [Related]
67. Key Guidelines in Developing a Pre-Emptive COVID-19 Vaccination Uptake Promotion Strategy. French J; Deshpande S; Evans W; Obregon R Int J Environ Res Public Health; 2020 Aug; 17(16):. PubMed ID: 32823775 [TBL] [Abstract][Full Text] [Related]
68. SARS-CoV-2 Infection: New Molecular, Phylogenetic, and Pathogenetic Insights. Efficacy of Current Vaccines and the Potential Risk of Variants. Rotondo JC; Martini F; Maritati M; Mazziotta C; Di Mauro G; Lanzillotti C; Barp N; Gallerani A; Tognon M; Contini C Viruses; 2021 Aug; 13(9):. PubMed ID: 34578269 [TBL] [Abstract][Full Text] [Related]
70. Considerations for fair prioritization of COVID-19 vaccine and its mandate among healthcare personnel. Hughes K; Gogineni V; Lewis C; Deshpande A Curr Med Res Opin; 2021 Jun; 37(6):907-909. PubMed ID: 33760673 [TBL] [Abstract][Full Text] [Related]
71. Fight against hesitancy: public health concern towards COVID-19 vaccine. Punsalan MLD J Public Health (Oxf); 2021 Jun; 43(2):e372. PubMed ID: 33730162 [TBL] [Abstract][Full Text] [Related]
72. Vaccination in the Philippines: experiences from history and lessons for the future. Reyes MSGL; Dee EC; Ho BL Hum Vaccin Immunother; 2021 Jun; 17(6):1873-1876. PubMed ID: 33357156 [TBL] [Abstract][Full Text] [Related]
75. COVID-19 Vaccinations: Medical, Ethical and Legal Aspects. Alazzam FAF; Shakatreh HJM; Gharaibeh ZIY; Aldrou KKAR; Alkhatib AJ Med Arch; 2022 Dec; 76(6):413-418. PubMed ID: 36937616 [TBL] [Abstract][Full Text] [Related]
76. Severe breakthrough COVID-19 infections in Scotland-implications for immunisation programmes. Leshem E; Nelson K; Lopman BA Lancet Respir Med; 2021 Dec; 9(12):1354-1356. PubMed ID: 34599904 [No Abstract] [Full Text] [Related]
77. COVID-19 in Romania: What Went Wrong? Dascalu S; Geambasu O; Valentin Raiu C; Azoicai D; Damian Popovici E; Apetrei C Front Public Health; 2021; 9():813941. PubMed ID: 34976942 [No Abstract] [Full Text] [Related]
78. COVID-19 Vaccination and Cancer: Correspondence. Mungmunpuntipantip R; Wiwanitkit V Asian Pac J Cancer Prev; 2021 Nov; 22(11):3417. PubMed ID: 34837894 [No Abstract] [Full Text] [Related]
79. Covid-19 Massive Vaccination Center Layouts. Brambilla A; Mangili S; Macchi M; Trucco P; Perego A; Capolongo S Acta Biomed; 2021 Oct; 92(S6):e2021446. PubMed ID: 34739468 [TBL] [Abstract][Full Text] [Related]
80. Value judgments in a COVID-19 vaccination model: A case study in the need for public involvement in health-oriented modelling. Harvard S; Winsberg E; Symons J; Adibi A Soc Sci Med; 2021 Oct; 286():114323. PubMed ID: 34428600 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]